Australian Authorities Spoil Sigma Money-Saving Merger
This article was originally published in PharmAsia News
Executive Summary
An Australia grocery wholesaler canceled plans to buy Primary Health Care's pharmaceuticals distribution business, Symbion. Primary had obtained the pharmaceuticals business when it bought Symbion Health. Wholesaler Metcash had been considering the buy in part because it has a joint-venture and logistics plan with Sigma Pharmaceuticals. Sigma had hoped to save millions a year with the proposed merger, and is expected to consider ties with other firms to make a new bid for Symbion. Primary's offer apparently was scuttled when Australian authorities failed to approve its purchase of Symbion. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.